Abstract | BACKGROUND: We previously demonstrated that lovastatin decreases cyst volume and improves kidney function in the Han:SPRD (Cy/+) rat model of ADPKD. Since endothelial dysfunction and inflammatory activity are evident in patients with ADPKD, we investigated whether lovastatin reduces the inflammation and vascular dysfunction and improves kidney cell energy metabolism of Cy/+ rats. METHODS: Cy/+ and normal littermate control animals (+/+) were treated with either lovastatin (4 mg/kg/day) or vehicle ( ethanol) from 3-8 weeks of age. 1H-NMR analysis was performed on water-soluble and lipid kidney fractions following perchloric acid extraction. Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to assess endothelial dysfunction, oxidative stress and inflammation markers in plasma and kidney tissue extracts. RESULTS: CONCLUSION: As previously described, lovastatin was able to decrease kidney weight and cyst volume density in Cy/+ rats. The decrease in cyst volume was accompanied by a reduction in arachidonic acid-mediated inflammation markers, the normalization of metabolism of NO precursors and the improvement of kidney energy cell metabolism.
|
Authors | Jelena Klawitter, Iram Zafar, Jost Klawitter, Alexander T Pennington, Jacek Klepacki, Berenice Y Gitomer, Robert W Schrier, Uwe Christians, Charles L Edelstein |
Journal | BMC nephrology
(BMC Nephrol)
Vol. 14
Pg. 165
(Jul 31 2013)
ISSN: 1471-2369 [Electronic] England |
PMID | 23902712
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Disease Models, Animal
- Lovastatin
(therapeutic use)
- Male
- Polycystic Kidney Diseases
(drug therapy, metabolism)
- Rats
- Treatment Outcome
|